AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and ...

Dive Brief: Actio Biosciences, a San Diego-based biotechnology startup, announced Wednesday it raised a $66 million Series B financing to support drug research it’s initially aiming at rare genetic ...

Psychiatric medicine remains one of the more challenging and risky areas of drug research. Many prospects show initial promise only to fail later on. Still, recent breakthroughs are spurring more ...

Bristol-Myers Squibb is looking to revive the fortunes of Opdivo by combining it with a next-generation immunotherapy, and has presented some favourable early-stage safety data. Yesterday was ...

BMS’ Opdivo, used in combination with chemotherapy, is now allowed in advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancers only among patients whose tumors ...